BENGALURU : Gilead Sciences Inc said on Monday that it plans to begin clinical trials of an inhaled version of its antiviral treatment remdesivir for COVID-19 patients in August.The drug is currently used intravenously and an inhaled formulation would be given through a nebulizer, which could potentially allow for easier administration outside hospitals, the company said in a statement.Click here to read the Mint ePaperLivemint.com is now on Telegram.